Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Inclusion Criteria

• •Must be on a stable background Methotrexate (MTX) therapy prior to Day1/Randomization. Subjects must have taken MTX for at least 3 months at a dose ≥ 15 mg/week to a maximum weekly dose of ≤ 25 mg/week, and be at a stable dose for 4 weeks prior to randomization (Day 1). Methotrexate dose ≥ 15 mg/week that was not efficacious and that was decreased due to toxicity as low as 10 mg/week is allowed
• •Inadequate response to NSAID and/or non-biologic DMARD
• •Minimum of 3 swollen and 3 tender joints
• •Active psoriatic skin lesions over minimum 3% body surface area
• •high sensitivity C-reactive protein (hsCRP) ≥ 0.3 mg/dL